Posted on

Vireo Health Expands National Footprint with Entry into Arizona’s Medical Cannabis Market

MINNEAPOLIS, March 25, 2019 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CSE: VREO), America’s leading science-focused, multi-state cannabis company, today announced the acquisition of four entities which together manage the vertically-integrated medical cannabis business of license-holder Arizona Natural Remedies (“ANR”). The acquisition includes a cultivation and processing facility in Amado, a wholesale business that distributes products to third-party dispensaries throughout the state, and a dispensary in Phoenix.

Vireo Logo

“With today’s acquisition, Vireo expands its business into the Grand Canyon State’s rapidly growing medical cannabis market,” said Chief Executive Officer, Kyle Kingsley, M.D. “ANR is a recognized leader in all-natural, organic, and pesticide-free cultivation and has done a tremendous job of building consumer trust and loyalty at their Phoenix dispensary. We look forward to welcoming ANR team members into the Vireo family and combining their core competencies with our medical, scientific, and manufacturing expertise.”

Arizona is one of the largest medical cannabis markets in the United States. According to the Arizona Department of Health Services, in February 2019, there were 191,683 active qualifying patients enrolled in the state’s medical cannabis program.

This transaction, which was previously disclosed, was financed through a combination of cash and stock and represents Vireo’s first acquisition since it began trading on the Canadian Securities Exchange under the ticker symbol “VREO.” The Company now has more than 300 employees across operations in seven states including Arizona, Maryland, Minnesota, New York, Ohio, Pennsylvania, and Rhode Island.

About Vireo Health International, Inc.

Vireo Health International, Inc. is America’s leading science-focused, multi-state cannabis company. Vireo’s physician-led team of more than 300 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally-friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company currently has operations in seven states including Arizona, Maryland, Minnesota, New York, Ohio, Pennsylvania, and Rhode Island.  For more information about the company, please visit www.vireohealth.com.

Contact Information 

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com   
(267) 221-4800

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward-Looking Statement Disclosure

This news release contains forward-looking information within the meaning of applicable securities laws, based on current expectations. Generally, any statements that are not historical facts may contain forward-looking information, and forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “look forward to”, “budget” “scheduled”, “estimates”, “forecasts”, “will continue”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or indicates that certain actions, events or results “may”, “could”, “would”, “might” or “will be” taken, “occur” or “be achieved.” Forward looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of Vireo, and includes statements about, among other things, future developments, the future operations, strengths and strategy of the Company. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results. These statements are based upon certain material factors, assumptions and analyses that were applied in drawing a conclusion or making a forecast or projection, including Vireo’s experience and perceptions of historical trends, current conditions and expected future developments, as well as other factors that are believed to be reasonable in the circumstances.

Examples of the assumptions underlying the forward-looking statements contained herein include, but are not limited to those related to: the achievement of goals, the closing of acquisitions, obtaining of necessary permits and governmental approvals, future market positioning, as well as expectations regarding availability of equipment, skilled labor and services needed for cannabis operations, intellectual property rights,  development, operating or regulatory risks, trends and developments in the cannabis industry, business strategy and outlook, expansion and growth of business and operations, the timing and amount of capital expenditures; future exchange rates; the impact of increasing competition; conditions in general economic and financial markets; access to capital; future operating costs; government regulations, including future legislative and regulatory developments involving medical and recreational marijuana and the timing thereto; receipt of appropriate and necessary licenses in a timely manner; the effects of regulation by governmental agencies; the anticipated changes to laws regarding the recreational use of cannabis; the demand for cannabis products and corresponding forecasted increase in revenues; and the size of the medical marijuana market and the recreational marijuana market.

Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that it will be completed on the terms described above and that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. Vireo assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

By its nature, forward-looking information is subject to risks and uncertainties, and there are a variety of material factors, many of which are beyond the control of the Company and that may cause actual outcomes to differ materially from those discussed in the forward-looking statements. These factors include, but are not limited to: denial or delayed receipt of all necessary consents and approvals; need for additional capital expenditures; increased costs and timing of operations; unexpected costs associated with environmental liabilities; requirements for additional capital; reduced future prices of cannabis; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes and other risks of the cannabis industry; delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities; title disputes; claims limitations on insurance coverage; risks related to the integration of acquisitions; fluctuations in the spot and forward price of certain commodities (such as diesel fuel and electricity); changes in national and local government legislation, taxation, controls, regulations and political or economic developments in the countries where the Company may carry on business in the future;  liabilities inherent in cannabis operations;  risks relating to medical and recreational cannabis; cultivation, extraction and distribution problems; competition for, among other things, capital, licences and skilled personnel;  risks relating to the timing of legalization of recreational cannabis; changes in laws relating to the cannabis industry; and management’s success in anticipating and managing the foregoing factors.

 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-expands-national-footprint-with-entry-into-arizonas-medical-cannabis-market-300817579.html

SOURCE Vireo Health, Inc.

Posted on

Why Physicians Founded Vireo Health

For Dr. Kyle Kingsley, a trained emergency medical doctor in Minnesota, his perspective on the use of medical cannabis evolved after meeting a Gulf War veteran who had suffered a gunshot wound resulting in a spinal cord injury. For years, the veteran was experiencing debilitating pain and found no relief from the large amounts of prescribed opiates. Finally, he chose to try medical cannabis, which provided him significant relief with little to no sides effects and helped pave the way for him to lead a normal and pain-free life.

Experiences like this inspired Dr. Kingsley to create Vireo Health, a physician-led company dedicated to providing patients with best-in-class cannabis-based products and high-quality care.

Vireo’s Minnesota operation scored first out of a dozen applicants in the highly competitive, merit-based Minnesota medical cannabis licensing process. Vireo then launched Vireo Health of New York, winning one of only five available medical cannabis licenses in the Empire State, with more than 40 applicants. In 2018, Vireo Health was awarded a license to grow and manufacture medical cannabis products in Pennsylvania.

Today, the Vireo Health team is comprised of physicians, scientists, pharmacists and horticulturists that have a wealth of experience and knowledge. Vireo Health’s subsidiaries – Vireo Health of New York, Minnesota Medical Solutions and Pennsylvania Medical Solutions – cultivate cannabis in their environmentally friendly greenhouses and manufacture pharmaceutical-grade cannabis extracts in their state-of-the art labs.

Vireo Health’s “Spectrum” of products range from THC-dominate to CBD-dominate and come in a variety of applications including vape cartridges, oral solutions and capsules. Many of these items are now available to dispensaries and patients across Pennsylvania, all produced locally at our facilities in Scranton, PA.

As Pennsylvania Medical Solutions continues to grow, their mission of “seed to sale” or “plant to patient” is coming to life across the state. Vireo products are now available in 80 percent of Pennsylvania dispensaries, and currently Vireo is the only medical marijuana grower and processor in the state to offer 1000mg vaporizer cartridges. Vireo is greatly expanding their greenhouse and operating facilities in Scranton, PA and expanding their workforce and product lines to ensure their high-quality products are accessible to patients throughout the Keystone State.

Vireo Health also places a strong focus on increasing education and awareness about the efficacy and safety of medical cannabis. Vireo Health partners with many local and national research organizations ranging from educational institutes like the University of Minnesota and University of Iowa to medical research groups like Montefiore Medical Center and the MMJ.org initiative run by Thomas Jefferson University.

To learn more about Vireo Health’s commitment to best-in-class product formulations and commitment to patient care via medical cannabis, please visit: www.vireohealth.com/pa.

Check out the original article here: http://dispensemagazine.com/why-physicians-founded-vireo-health/

Posted on

Spherix Announces Ownership Interest in Electric Scooter Business

The Next Generation of Human Transportation Meets Innovation in Ownership

NEW YORK, Nov. 26, 2018 /PRNewswire/ — Spherix Incorporated (Nasdaq: SPEX) today announced it has secured an ownership interest in Mellow Scooters, LLC, a leading-edge company that enables anyone to own and operate a personal fleet of electric scooters and dockless bicycles to generate revenue.

Spherix Logo. (PRNewsFoto/Spherix Incorporated)

Mellow’s unique system allows entrepreneurs both small and large scale to operate a local business leveraging Mellow’s proprietary software. From renting out an unused road bike, to running a fleet of hundreds of electric scooters, Mellow provides a flexible entry for anyone interested in the growing shared vehicles space. The Mellow website, www.ridemellow.com, explains the concept of the system through its Mellow Owner and Rider walkthrough guides.

“We believe in empowering citizens, small businesses, and cities to localize operation of shared vehicles and keep the generated revenue for schools, infrastructure and the betterment of their own shared spaces. We have closely studied this fast-growing area of human transportation and believe we have identified a tremendous opportunity to change who can participate in this developing space.  The core of Mellow’s business, enabling local economies to keep revenue generated through transit, is an equitable approach designed to provide a safer, more stable environment. Instead of giving a distant business control of a city’s transit, cities and small businesses can elect to run their own Mellow operation and harness revenue from last mile transit. The current state of private companies taking advantage of city resources (i.e. sidewalk space, emergency dispatch teams, transit revenue) appears to be unfair and potentially unsustainable in the long term,” stated Chris Hoyle, CEO of Mellow.

Anthony Hayes, CEO of Spherix commented, “Leading up to our acquisition of CBM BioPharma, Spherix had been incubating Mellow and we are proud of its advancements.  Mellow is uniquely positioned to take advantage of a gap in the rapidly growing electric scooter and bike sharing business and we are proud to now own twenty five percent (25%) of Mellow.  Chris Hoyle is an exceptional, bright entrepreneur and we are excited to support his vision. Our ownership interest in Mellow gives our shareholders the potential opportunity to participate in the electronic scooter and bike sharing industry, while Spherix continues its commitment to the acquisition of CBM and the advancement of its important cancer fighting drugs.”

Additional information about the investment will be available in the Form 8-K, filed by Spherix with the Securities and Exchange Commission.

About Spherix

Spherix is committed to advancing innovation and technology by active participation in all areas of the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation. In addition to patent monetization efforts, Spherix has been transitioning to focus our efforts as a technology development company.  These efforts have focused on biotechnology research and blockchain technology research.  The Company’s biotechnology research development includes investments in Hoth Therapeutics Inc. and the proposed merger with CBM BioPharma, Inc. (“CBM”).  In the field of blockchain research, Spherix has invested in DatChat and The Bit Daily.  DatChat is a privately held personal privacy platform, focused on Encrypted Communication, Internet Security and Digital Rights Management.  The Bit Daily (www.thebitdaily.com) is a daily newsletter that summarizes the current blockchain and cryptocurrency news.

About Mellow Scooters, LLC

Mellow is a leading edge company that allows anyone to own and operate their personal fleet of dockless bicycles and electric scooters to generate revenue. For more information, go to www.ridemellow.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:      Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

Spherix:                       Phone: 212-745-1373
Email: investorrelations@spherix.com
www.spherix.com

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/spherix-announces-ownership-interest-in-electric-scooter-business-300754941.html

SOURCE Spherix Incorporated

News Provided by PR Newswire via QuoteMedia

Posted on

Spherix to Merge with CBM BioPharma Pharmaceutical Company

Transformative Merger Creates Innovative Biopharma Platform Poised for Growth

NEW YORK, Oct. 11, 2018 /PRNewswire/ — Spherix Incorporated (Nasdaq: SPEX) today announced that it has entered into a merger agreement with CBM BioPharma, Inc. (“CBM”) that will transform Spherix into an innovative pharmaceutical company with pioneering drugs and treatments focused on the multibillion dollar oncology therapeutics market.

Spherix Logo. (PRNewsFoto/Spherix Incorporated)

CBM is a privately held pharmaceutical company with exclusive drug development rights from world-renowned partners including Wake Forest Innovations and the University of Texas at Austin. CBM has a team of leading drug development scientists who will be joining Spherix as advisors to advance the technology. The CBM platform focuses on the treatment of numerous cancers, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and pancreatic cancer.

Two specific proprietary drugs that are currently being researched are:

KPC34 (Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Developed at Wake Forest School of Medicine, AML and ALL drug, KPC34, is a next generation treatment designed to overcome multiple resistance challenges observed with the current standard of care. KPC34 has also been shown to be more effective in AML relapse cases, notably increasing the lifespan of mice treated with the drug.

One competitive benefit of KPC34 includes its ability to be orally administered. This is critical for patients that are unable to tolerate repeated cycles of chemotherapy. In addition, it has served to double the mean survival time of patients versus the current standard of care treatments.

DHA-dFdC (Pancreatic Cancer Drug)

Developed at the University of Texas at Austin, DHA-dFdC has shown positive results in preclinical studies, inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models. DHA-dFdC also overcomes tumor cell resistance to current chemotherapeutic drugs.  Pancreatic cancer is a deadly disease that affects millions of people around the world.

The following doctors will be supporting the efforts of Spherix, after the completion of the merger:

Dr. Timothy S. Pardee, MD, PhD, an Associate Professor of Internal Medicine, Section on Hematology and Oncology and Cancer Biology and Director of Leukemia Translational Research at Wake Forest School of Medicine.  Dr. Pardee stated, “I am very excited at the possibility of bringing KPC34 to the clinic in early phase clinical trials. As a physician scientist who treats acute leukemia patients, I know firsthand the clear unmet medical need for relapsed patients.”

Dr. Gregory Kucera, a Professor of Internal Medicine at the Wake Forest University School of Medicine with over 28 years of research experience on novel therapeutics for cancer treatment. His laboratory has expertise in synthesizing therapeutics, lipid biochemistry, and in vitro drug testing.  Dr. Kucera stated, “As a research scientist, the satisfaction of seeing a compound like KPC34 go from the laboratory to an early stage clinical trial is immense.  I have a great sense of pride in knowing that the work done by our research team has produced a drug that may benefit cancer patients in the very near future.”

Joining Spherix as Chief Science Officer to oversee clinical advancement of these drugs is Dr. Tom Wilkie who is an Associate Professor of Pharmacology at the University of Texas Southwestern Medical Center in Dallas. He earned both his BA at the University of California Berkeley and his PhD with Richard Palmiter at UW Seattle, in biochemistry. Wilkie has published 74 primary research papers and reviews, serves on NIH, CIRM, and AACR grant review study sections. He reviews manuscripts for multiple journals, and is Director of the first-year graduate student core course at UT Southwestern.

Dr. Wilkie stated, “I’m delighted to join Spherix as Chief Science Officer.  The agreement between Spherix Incorporated and CBM BioPharma will advance the exciting potential for improving the lives of patients, family, friends, and ultimately, all of us.  Proposals for the next phase of testing are underway.”

Dr. Robert J. Vander Zanden, Spherix’s Chairman of the Board, stated, “Spherix is extremely pleased to announce this merger with CBM, as we believe it serves as a necessary step in our transition to a diversified biopharmaceutical company.  This deal builds upon our investment in Hoth Therapeutics, which owns several exciting assets in various stages of development.”

Anthony Hayes, CEO of Spherix stated, “We are very excited to welcome CBM BioPharma and its team to Spherix.  It is an exciting and transformational time for the Company. Spherix will pay $16.5 million in stock for 100% of CBM by issuing 15 million Spherix shares to CBM at a fixed price of $1.10 per share.  I look forward to sharing more information with our shareholders about the merger in the upcoming weeks, via investor outreach and our upcoming SEC filings.”

About Spherix

Spherix is committed to advancing innovation by active participation in all areas of the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation. Spherix has acquired over 100 patents from Rockstar Consortium Inc., and several hundred patents issued to Harris Corporation, covering a variety of methods and components involved in switching, routing, networking, optical and telecommunication sectors.

About CBM BioPharma, Inc.

CBM BioPharma, Inc. (www.cbmbiopharmainc.com) is a privately held pharmaceutical company with exclusive drug development rights from world renowned partners like Wake Forest University and University of Texas.  The Company has a team of leading drug development scientists who help advance their technology.  The CBM platform focuses on the treatment of numerous cancers, including acute myeloid leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and pancreatic cancer.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations: 

Hayden IR

Brett Maas, Managing Partner

Phone: (646) 536-7331

Email: brett@haydenir.com

www.haydenir.com

Spherix:

Phone: 212-745-1373

Email: investorrelations@spherix.com

www.spherix.com

 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/spherix-to-merge-with-cbm-biopharma-pharmaceutical-company-300729293.html

SOURCE Spherix Incorporated

News Provided by PR Newswire via QuoteMedia

Posted on

AbbVie Receives Health Canada Approval of ORILISSATM (elagolix) for the Treatment of Moderate to Severe Pain Associated with Endometriosis

  • Endometriosis affects up to one in 10 women of reproductive age in 1
  • 7 out of 10 women being managed for endometriosis have unresolved pain throughout the 2
  • The approval of ORILISSA is supported by data from two replicate Phase 3 studies, which evaluated nearly 1,700 women.
  • In clinical trials, ORILISSA™demonstrated sustained relief over 12 months across the two most common types of pain: dysmenorrhea and non-menstrual pelvic 3

 

 

Montreal, QC, October 5, 2018 –AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that Health Canada approved ORILISSA™ (elagolix), the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of moderate to severe pain associated with endometriosis.3

 

ORILISSA (elagolix) is a novel, orally administered, highly potent, short-acting, selective, non-peptide small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist that blocks endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of ORILISSA results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulation hormone (FSH) levels, leading to decreased blood levels of the ovarian sex hormones, estradiol and progesterone. LH and FSH suppression begins within hours of administration and is readily reversible upon discontinuation of ORILISSA.3

 

“Endometriosis causes a significant impact on the quality of life of women because of the debilitating and incapacitating pain. Women living with endometriosis can be sidelined by this disease,” says Dr. Nicholas A. Leyland, BASc, MD, MHCM, FRCSC, Chair of the Department of Obstetrics and Gynaecology, McMaster University. “Since there is no cure, the goal of treatment is to alleviate the symptoms and improve a woman’s quality of life. With ORILISSA, we are now able to offer our patients an additional new option that can help them resume living their lives.”

 

Endometriosis causes chronic pelvic pain and is sometimes associated with infertility. It affects up to one in 10 women of reproductive age in Canada.1 Furthermore, 7 out of 10 women being managed for endometriosis have unresolved pain throughout the month. 2

 

“Endometriosis is a complex and incurable disease. This is why early diagnosis is extremely important. Currently, on average, it takes seven to nine years of complaining about symptoms to medical professionals to receive a diagnosis of endometriosis. Therefore, earlier diagnosis and treatment can help mitigate years of unnecessary suffering,” explains Philippa Bridge-Cook, Ph.D., The Endometriosis Network Canada. “In addition, patients coping with symptoms without a diagnosis can sometimes face dismissal of their symptoms from friends, family, and even medical professionals. This can lead to feelings of isolation, anxiety, and depression.”

 

 

The approval of ORILISSA is supported by data from two replicate studies in the largest endometriosis Phase 3 study program conducted to date, which evaluated nearly 1,700 women with moderate to severe endometriosis pain. Clinical trial data demonstrated ORILISSA significantly reduced the two most common types of endometriosis pain: dysmenorrhea and non-menstrual pelvic pain. A higher proportion of women treated with ORILISSA 150 mg once daily and 200 mg twice daily were responders for daily menstrual pain and non-menstrual pelvic pain compared to placebo in a dose- dependent manner at month three. Women were defined as responders if they experienced a reduction in daily menstrual pain and non-menstrual pelvic pain with no increase in analgesic use (nonsteroidal anti-inflammatory drug or opioid) for endometriosis-associated pain. 3

 

Both ORILISSA treatment groups showed statistically significant greater mean decreases from baseline compared to placebo in daily menstrual pain and non-menstrual pelvic pain at month six. Women in the Phase 3 studies also provided a daily self-assessment of their endometriosis pain using a numeric rating scale (NRS) and women taking ORILISSA 150 mg once daily and 200 mg twice daily reported a statistically (p <0.001) significant reduction from baseline in NRS scores compared to placebo at month three. Clinical trial data also demonstrated women taking ORILISSA 200 mg twice daily showed statistically significant greater reduction in pain during sexual intercourse from baseline to month three compared to placebo. The most frequent (≥10%) adverse reactions reported in clinical trials with ORILISSA (elagolix) were hot flush, headache and nausea. 3

 

The recommended duration of use for ORILISSA is up to 12months for the 150 mg once daily dose and up to six months for the 200 mg twice daily dose, as it causes a dose-dependent decrease in bone mineral density (BMD). BMD loss is greater with increasing duration of use and may not be completely reversible after stopping treatment.3

 

“The approval of ORILISSA demonstrates AbbVie’s continued commitment to women living with endometriosis. We are proud of our heritage in women’s health and strive to fill the unmet medical need by providing a safe and efficacious treatment,” says Stéphane Lassignardie, General Manager of AbbVie Canada.

 

ORILISSA is expected to be available in Canadian retail pharmacies in early November 2018.

 

About AbbVie Care

Canadian women prescribed ORILISSA will have the opportunity to be enrolled in AbbVie Care, AbbVie’s signature care program. The program is designed to provide a wide range of customized services including reimbursement and financial support, pharmacy services, lab work reminders and coordination, personalized education and ongoing disease management support throughout the treatment and beyond. For more information, please visit www.abbviecare.ca.

 

About AbbVie

AbbVie is a global, research and development-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at

 

 

www.abbvie.ca and www.abbvie.com. Follow @abbvieCanada and @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

 

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, a San Diego based biopharmaceutical company, is focused on developing treatments for neurological and endocrine related disorders. The company discovered, developed and markets INGREZZA® (valbenazine), the first FDA approved product indicated for the treatment of adults with tardive dyskinesia, a movement disorder. Discovered and developed through Phase II clinical trials by Neurocrine, ORILISSA™ (elagolix), the first FDA-approved oral medication for the management of endometriosis with associated moderate to severe pain in over a decade, is marketed by AbbVie as part of a collaboration to develop and commercialize elagolix for women’s health. Neurocrine’s clinical development programs include opicapone as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in Parkinson’s disease patients, elagolix for uterine fibroids with AbbVie, valbenazine for the treatment of Tourette syndrome, and NBI-74788 for the treatment of congenital adrenal hyperplasia (CAH). For more information and the latest updates from Neurocrine, please visit www.neurocrine.com.

 

-30-

 

Media Inquiries:

Muriel Haraoui muriel.haraoui@abbvie.com 514.717.3764

 

1YourPeriod.ca – https://www.yourperiod.ca/endometriosis/what-is-endometriosis/

2De Graaff AA, D’Hooghe TM, Dunselman GAJ, Dirksen CD, Hummelshoj L, WERF EndoCost Consortium, Simoens S. The significant effect of endometriosis on physical, mental and social wellbeing: results from an international cross-sectional survey. Hum Reprod. 2013;28(10):2677-2685.

3Orilissa Product Monograph, AbbVie Corporation, October 5, 2018.

Posted on

Wuhan General Group/SDT Holdings (OTCBB: WUHN) Reports 140% Revenue Increase in its Consulting Division

MONTREAL, Aug. 14, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE — Wuhan General Group (China), Inc./ SDT Holdings, Inc.  (OTC PINK: WUHN) (the “Company”), an industrial technology company focused on creating industrial batteries and electric equipment for the mining, construction and agricultural industries announced today that for the period ended June 30, 2018, gross revenue from its consulting services division increased 140 percent as compared to the same period in the previous year. Gross revenue for the period ended June 30, 2018 was $154,000 as compared to $64,000 for the same period in the previous year. In addition, the company has begun to see positive cash flow in the second quarter of 2018.

“Our consulting-services team achieved a strong six months characterized by solid revenue growth and major core development, while navigating this challenging phase of going public,” said CEO Ramy Kamaneh.

Mr. Kamaneh continued, “As many industries move away from gas and diesel power and adopt electric vehicles and other equipment, we expect to see a pattern of high double digit revenue growth going forward. Our deep understanding of the specifications for these industrial batteries along with the in-field operations of various industries allows us to have a competitive advantage when we are asked to provide a solution for some of North America’s largest companies.”

About SDT Holdings, Inc.

SDT Holdings, Inc. is a Nevada corporation  engaged in the research, development and manufacturing of industrial battery technologies and electric Material handling equipment (eMHE) to assist the mining, construction and agricultural industries in eliminating greenhouse gas (GHG) emissions by moving from diesel power to a battery-powered energy source. SDT’s deep understanding of battery chemistry and the in-field operations for industries such as the underground mining industry, gives it a competitive advantage to become a leader in the development of this space as well as in assisting these industries in their adoption to battery powered material handling equipment.

By complementing its industrial batteries and eMHE with predictive maintenance using artificial intelligence and hardware (Internet of things), SDT can effectively manage and coordinate a full-scale battery-powered operation and charging infrastructure 24-7 at some of the most remote locations in the world.

SDT Holdings, Inc. is also  exploring the research and application of blockchain technologies to the mining, agriculture and construction industries.

SDT Holdings, Inc
Publicly traded company (OTC Pink: WUHN)
Website: www.sdtholdings.com

For further information contact:
Contact: Bruce Haase – Public Relations
Phone: (514) 928-7368 Ext 6
E-mail: info@sdtholdings.com

Forward-Looking Statements
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that would cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Source: Wuhan General Group (China), Inc

Posted on

Wuhan General Group/SDT Holdings (OTC PINK: WUHN) Reports 140% Revenue Increase in its Consulting Division

MONTREAL, QC / ACCESSWIRE / August 13, 2018 / Wuhan General Group (China), Inc./ SDT Holdings, Inc. (OTC PINK: WUHN) (the “Company”), an industrial technology company focused on creating industrial batteries and electric equipment for the mining, construction and agricultural industries announced today that for the period ended June 30, 2018, gross revenue from its consulting services division increased 140 percent as compared to the same period in the previous year. Gross revenue for the period ended June 30, 2018 was $154,000 as compared to $64,000 for the same period in the previous year. In addition, the company has begun to see positive cash flow in the second quarter of 2018.

“Our consulting-services team achieved a strong six months characterized by solid revenue growth and major core development, while navigating this challenging phase of going public,” said CEO Ramy Kamaneh.

Mr. Kamaneh continued, “As many industries move away from gas and diesel power and adopt electric vehicles and other equipment, we expect to see a pattern of high double digit revenue growth going forward. Our deep understanding of the specifications for these industrial batteries along with the in-field operations of various industries allows us to have a competitive advantage when we are asked to provide a solution for some of North America’s largest companies.”

About SDT Holdings, Inc.

SDT Holdings, Inc. is a Nevada corporation engaged in the research, development and manufacturing of industrial battery technologies and electric Material handling equipment (eMHE) to assist the mining, construction and agricultural industries in eliminating greenhouse gas (GHG) emissions by moving from diesel power to a battery-powered energy source. SDT’s deep understanding of battery chemistry and the in-field operations for industries such as the underground mining industry, gives it a competitive advantage to become a leader in the development of this space as well as in assisting these industries in their adoption to battery powered material handling equipment.

By complementing its industrial batteries and eMHE with predictive maintenance using artificial intelligence and hardware (Internet of things), SDT can effectively manage and coordinate a full-scale battery-powered operation and charging infrastructure 24-7 at some of the most remote locations in the world.

SDT Holdings, Inc. is also exploring the research and application of blockchain technologies to the mining, agriculture and construction industries.

SDT Holdings, Inc
Publicly traded company (OTC Pink: WUHN)
Website: www.sdtholdings.com

For further information contact:

Contact: Bruce Haase – Public Relations
Phone: (514) 928-7368 Ext 6
E-mail: info@sdtholdings.com

Forward-Looking Statements

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that would cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

 

SOURCE: Wuhan General Group (China), Inc

Posted on

AbbVie’s MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes

  • MAVIRET is the first and only 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment*1
  • The approval is supported by a 97 percent (n=639/657) cure** rate across GT1-6 patients without cirrhosis and who are new to treatment2
  • MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease

 

MONTREAL, QC, August 17, 2017 – AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that Health Canada has granted approval for MAVIRET™ (glecaprevir/pibrentasvir tablets), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6). MAVIRET is the only 8-week, pan-genotypic treatment for patients without cirrhosis and who are new to treatment,* who make up a large portion of HCV patients in Canada.

 

“Despite recent advances in HCV treatment, physicians still face challenges treating patients with less common genotypes and those with other complicating health conditions,” said Dr. Morris Sherman, MD, FRCPC, Chairperson, Canadian Liver Foundation. “In order to eliminate hepatitis C in Canada, we need to identify all those living with the virus and have effective treatment options for everyone. This new therapy provides another tool for physicians to expand treatment to a greater number of patients while at the same time shortening the duration which may lead to cost savings for the health care system.”

 

MAVIRET is also approved for use in patients with specific treatment challenges, including those with compensated cirrhosis across all major genotypes, and those who previously had limited treatment options, such as patients with severe chronic kidney disease (CKD), those GT1 patients not previously cured with certain direct-acting antiviral (DAA) treatment, and those with GT3 chronic HCV infection.2 MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of CKD.2

 

“With the approval of MAVIRET, we are proud to bring the hope of a new cure to people living with hepatitis C in Canada, reflecting AbbVie’s dedication to addressing critical unmet needs for patients,” said Stéphane Lassignardie, General Manager, AbbVie Canada. “MAVIRET is designed to deliver a virologic cure for most HCV patients including those with specific treatment challenges. AbbVie will continue to work with local health authorities and stakeholders across Canada to get our treatment to as many patients as possible.”

 

The efficacy and safety of MAVIRET was evaluated in nine Phase 2-3 clinical trials, in over 2,300 patients with genotype 1, 2, 3, 4, 5 or 6 HCV infection and with compensated liver disease (with or without cirrhosis).

 

Approximately 300,000 Canadians are infected with hepatitis C.3 In 2012 alone, more than 10,000 new cases of hepatitis C were reported, but 40 percent of patients are estimated to be living unaware of their disease.4 GT1 is the most common genotype in Canada and GT3 is the most difficult to treat.3,5 Over time chronic hepatitis C can lead to chronic liver diseases, with a risk of developing cirrhosis of up to

30 percent within 20 years6 of infection. Additionally, HCV is common among people with severe CKD, and some of these patients previously did not have a DAA-based treatment option.7

 

With 8 weeks of treatment, 97 percent (n= 639/657) of GT1-6 patients without cirrhosis and who were new to treatment achieved a virologic cure.1 These high cure rates were achieved in patients with varied patient and viral characteristics and including those with CKD.2 Additionally, 97.5 percent (n=274/281) of patients with compensated cirrhosis achieved a virologic cure with the recommended duration of treatment, including patients with CKD.2 In registrational studies for MAVIRET, less than 0.1 percent of patients permanently discontinued treatment due to adverse reactions.2 The most commonly reported adverse reactions (incidence greater than or equal to 10 percent) were headache and fatigue.2

 

“In an extensive clinical trial program, patients achieved high cure rates with MAVIRET regardless of genotype, fibrosis score, viral load, and even in patients with resistant virus strains and those with chronic kidney disease,” said Dr. Magdy Elkhashab, Gastroenterologist/Hepatologist, Director of the Toronto Liver Centre. “In clinical practice, MAVIRET has the potential to simplify treatment decisions for physicians, offering, in one therapy, a cure for the majority of HCV patients and cutting out pre-testing before treatment initiation.”

 

MAVIRET combines two new, potent direct-acting antivirals that target and inhibit proteins essential for the replication of the hepatitis C virus.2 The presence of most genotypes or baseline mutations that are commonly associated with resistance have been shown to have no relevant impact on efficacy. 2

 

Canadians prescribed MAVIRET will have the opportunity to be enrolled in AbbVie Care, AbbVie’s signature patient support program designed to provide a wide range of services including reimbursement assistance, education and ongoing disease management support. AbbVie Care will support people living with HCV throughout their treatment journey to achieve high cure rates in the real world.

 

Approval of MAVIRET followed Health Canada’s Priority Review process, which is granted to new medicines intended for patients with a life-threatening disease where there is no existing treatment with the same profile or where the new product represents a significant improvement in the benefit/risk profile over existing products.8 AbbVie’s investigational, pan-genotypic regimen was also recently approved by the European Commission and the U.S. Food and Drug Administration.

 

About MAVIRET™

MAVIRET™ is approved in Canada for the treatment of chronic hepatitis C virus (HCV) infection in adults across all major genotypes (GT1-6).2 MAVIRET is a new, pan-genotypic, once-daily, ribavirin-free treatment that combines glecaprevir (100 mg), an NS3/4A protease inhibitor, and pibrentasvir (40 mg), an NS5A inhibitor, dosed once-daily as three oral tablets.2

 

MAVIRET is an 8-week, pan-genotypic virologic cure** for use in patients without cirrhosis and who are new to treatment,* such patients comprising the majority of people living with HCV.1 MAVIRET is also approved as a treatment for patients with specific treatment challenges, including those with compensated cirrhosis across all major genotypes, and those who previously had limited treatment

 

options, such as patients with severe chronic kidney disease (CKD) and those with genotype 3 infection.2 It is the only pan-genotypic treatment approved for use in patients across all stages of CKD.2

Glecaprevir (GLE) was discovered during the ongoing collaboration between AbbVie and Enanta Pharmaceuticals (NASDAQ: ENTA) for HCV protease inhibitors and regimens that include protease inhibitors.

 

*Patients without cirrhosis and new to treatment with DAAs [either treatment-naive or not cured with previous IFN-based treatments ([peg]IFN +/- RBV or SOF/RBV +/- pegIFN)].

**Patients who achieve a sustained virologic response at 12 weeks post treatment (SVR12) are considered cured of hepatitis C.

 

 

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com. Follow @abbvieCanada and @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

 

###

 

Media:

Muriel Haraoui AbbVie Canada (514) 717-3764

muriel.haraoui@abbvie.com

 

 

1 Decisions Resources Group. Hepatitis C virus: disease landscape & forecast 2016. January 2017.

2 MAVIRET (glecaprevir/pibrentasvir tablets) Product Monograph. Date of Preparation: August 16, 2017.

3 Messina, JP et al. “The global distribution of HCV genotypes.” Hepatology, 2015; 61: 77–87. Supporting information hep27259- sup-0001-suppinfo.pdf. Accessed August, 2017.

4 Hepatitis C: Get the Facts. Government of Canada. https://www.canada.ca/en/public-health/services/publications/diseases- conditions/poster-hepatitis-c-get-facts.html. Accessed August, 2017.

5 Wyles, D et al. SURVEYOR-II, Part 3: Efficacy and Safety of ABT-493/ABT-530 in Patients with Hepatitis C Virus Genotype 3 Infection with Prior Treatment Experience and/or Cirrhosis. Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, US on November 11-15, 2016.

6 Hepatitis C Fact Sheet. World Health Organization. World Health Organization, July 2017. Web. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed August, 2017.

7 Fabrizi F, Poordad FF, Martin P. Hepatitis C infection in the patient with end stage renal disease. Hepatology. 2002;36(1):3-10. 8 Priority Review of Drug Submissions. Government of Canada. https://www.canada.ca/en/health-canada/services/drugs- health-products/drug-products/fact-sheets/priority-review-drug-submissions-therapeutic-products.html. Accessed August, 2017.

Posted on

AbbVie IBD Scholarship expands in celebration of Canada 150

Toronto, ON – June 28, 2017 – In celebration of Canada 150, Crohn’s and Colitis Canada and AbbVie announced today that five additional AbbVie IBD Scholarships of up to $5,000 will be awarded to students who live with Crohn’s disease or ulcerative colitis for the upcoming school year, bringing the total number of scholarships offered to 15.

 

“Canada has one of the highest rates of inflammatory bowel disease (IBD) in the world, with most cases diagnosed in individuals between the ages of 15 and 30,” said Mina Mawani, President and CEO of Crohn’s and Colitis Canada. “As one in 150 Canadians live with Crohn’s disease or ulcerative colitis, Canada 150 is an important opportunity to raise awareness of these chronic diseases, and these scholarships benefit young Canadians during a difficult time in their lives.”

 

“This year, Crohn’s and Colitis Canada received a record number of scholarship applications at just under

  1. The recipients of the scholarship will be determined by the selection committee,” said Kate Lee, Vice President, Research and Patient Programs.

 

“We are extremely proud of our longstanding partnership with Crohn’s and Colitis Canada on the AbbVie IBD Scholarship Program,” says Stéphane Lassignardie, General Manager of AbbVie Canada. “Since 2012, the AbbVie IBD Scholarship has supported nearly 60 Canadian students navigating post-secondary education while living with a chronic disease and we are pleased to extend our support to even more youth this year in celebration of Canada 150.”

 

Past recipients of the AbbVie IBD Scholarship credit the program for helping them focus on their studies while offering a platform to share their advice and experience with other students living with Crohn’s or colitis. Rachel Meehan received the scholarship in 2016 while completing her master’s degree from the University of Guelph. “During my undergrad, I took on too much at once and didn’t appropriately manage the symptoms of my Crohn’s disease,” said Meehan. “Receiving the AbbVie IBD Scholarship meant one less thing to worry about when I returned to school for my master’s degree.”

 

The five additional recipients will be selected from applications received during the initial call for applications, which closed on June 1, 2017.

 

 

 

 

 

###

 

About the AbbVie IBD Scholarship

In its sixth year, the annual AbbVie IBD Scholarship Program will recognize 15 individuals across Canada who are living with Crohn’s disease or ulcerative colitis. Each winner is awarded an educational grant of up to $5,000 CAD. The scholarship is available to students of any age who are enrolled in a Canadian post-secondary educational institution in 2017. Visit ibdscholarship.ca for more information.

 

About Crohn’s and Colitis Canada

Crohn’s and Colitis Canada is the only national, volunteer-based charity focused on finding the cures for Crohn’s disease and ulcerative colitis and improving the lives of children and adults affected by these diseases. We are one of the top two health charity funders of Crohn’s and colitis research in the world, investing over $100 million in research to date. We are transforming the lives of people affected by Crohn’s and colitis (the two main forms of inflammatory bowel disease) through research, patient programs, advocacy and awareness. Visit crohnsandcolitis.ca for more information. Follow us on Twitter, Facebook or Instagram at @getgutsycanada.

 

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us

at www.abbvie.ca or follow us on Twitter at @abbviecanada

 

For more information, or to arrange interviews, please contact:

 

Corey Michaels

Smithcom Ltd. corey.michaels@smithcom.ca 416-894-4704

 

Rasheed Clarke

Crohn’s and Colitis Canada rclarke@crohnsandcolitis.ca 416-920-5035, ext. 215

Posted on

MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board

MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Peter Bergethon, a world-leading expert in neurology, digital medicine, and central nervous system (CNS) drug development to the Company’s Scientific Advisory Board.

Dr. Bergethon is the Vice President and Head of Digital and Quantitative Medicine at Biogen Inc., where he leads the effort to transform clinical trials and humanize drug discovery by encouraging the transition of clinical trial measures from a qualitative to a quantitative discipline. The Quantitative Medicine transformation has advanced Biogen’s leadership in neuroscience therapeutics and personalized medicine. Dr. Bergethon came to Biogen in 2017 from Pfizer Worldwide Research and Development where he was Vice President and Head of the Pfizer Innovation Research Lab within the Early Clinical Development group.

Before joining the biopharmaceutical industry in 2012, Dr. Bergethon spent 30 years in academic medicine as a Professor at Boston University and Tufts University in the Departments of Biochemistry, Neurology, Neurobiology & Anatomy, and Biomedical Engineering. Dr. Bergethon graduated from Williams College with honors in biology for research in neurocybernetics and then earned an M.D. from Jefferson Medical College. He is board-certified in internal medicine and neurology following dual residencies at Boston City Hospital. Dr. Bergethon received his formal science training through the National Institutes of Health’s Physician-Scientist training in biophysical chemistry at Boston University School of Medicine. He then completed a fellowship training in EEG and neurophysiology at Lahey Clinic-Hitchcock Medical Center in Burlington, MA. In 1995, Dr. Bergethon received the American Academy of Neurology’s Founders’ Award. Dr. Bergethon has written and contributed to over 130 research papers and books and is the single author of “The Physical Basis of Biochemistry: The Foundations of Molecular Biophysics”, 2nd Ed.

MindMed CEO Robert Barrow said, “We are thrilled to welcome Dr. Bergethon to our Scientific Advisory Board. As we seek to revolutionize mental health and addiction care, we continue to explore ways of leveraging innovative digital medicine approaches to facilitate broad accessibility and major public health impacts. Dr. Bergethon’s extensive experience in this field will be invaluable in progressing all of our research and development efforts.”

Dr. Bergethon stated, “My research and interests have always centered around a core question: ‘What are the physical and systemic bases for creativity and intelligent behavior, and how could such behavior be practically constructed or reconstructed?’ This core query continues to form the basis for the approach that digital medicine takes toward transforming neuroscience therapeutics. The ultimate thrust of my interest is the design, construction, and operation of ‘intelligent machines’ inspired by biological understanding. By any measure, I have lived a charmed scientific existence.”

MindMed’s Scientific Advisory Board is composed of a diverse group of members with expertise in psychiatry, neuroscience, and clinical development. The Scientific Advisory Board leverages decades of deep knowledge in biotech and psychiatry to guide MindMed’s development programs. Members represent institutions such as Johns Hopkins, New York University Langone Health, Duke University, National Institutes of Health (NIH), Stanford University, and Albany Medical College.

Scientific Advisory Board Chair, Dr. Robert Malenka added, “We are very excited to welcome Dr. Bergethon to the Scientific Advisory Board. He brings a wealth of experience and innovative thinking to MindMed’s digital medicine efforts and will be invaluable in helping MindMed be the world leader in developing effective new treatments based on the most rigorous science.”

About MindMed
MindMed is a clinical-stage biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental health. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed’s approach of developing the next generation of psychedelic inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ. For more information: www.mindmed.co

MindMed Forward-Looking Statements
Certain statements in this news release related to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “will”, “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “potential” or “continue”, or the negative thereof or similar variations. Forward-looking information in this news release include statements regarding the expertise of the Scientific Advisory Board and ability to leverage the knowledge of the Scientific Advisory Board, the ability to develop and the potential success of using technology to improve health outcomes, the pursuit of strategic initiatives, and the Company’s intended future business plans and operations, including the development of psychedelic inspired medicines and experiential therapies. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described under the headings “Risk Factors” in the Company’s filings with the securities regulatory authorities in all of the provinces and territories of Canada and available under the Company’s profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.